Naltrexone

Naltrexone is an opioid antagonist medication that works by blocking the effects of opioids. Patients taking naltrexone receive a monthly injection, which reduces cravings for heroin/opioids and also blocks the brain’s opioid receptors from the patient feeling any euphoric effects should they impulsively use heroin. Naltrexone cannot be administered to a patient until he or she has been totally withdrawn from opioids (a procedure known as detoxification) and has been opioid-free for at least 7 days. Naltrexone prevents relapse and can also be used by patients who have been in treatment and have tapered off buprenorphine as an added protection against relapse.

Related Training Resources

Presenter(s):
Adam Fussaro, LSW, LCSW, and Kristina Scalia-Jackson, BA
Credit Available:
CE Credit(s): No
Certificate: Certificate of Attendance, 1-hour
According to the Centers for Disease Control (CDC), more than 111,000 people died from a drug overdose in the 12-month period ending last September. Unhoused individuals are especially at risk of overdose deaths. Recent studies show that of people experiencing homelessness, drug-overdose accounted for 1 in 4 deaths. As drug-related overdose deaths continue to rise, the need for innovative, early intervention and harm-reducing services are especially relevant. Programs across the country have begun to develop strategies to reduce harm in these at-risk populations. Come join us as we profile one such program that is focused on providing life-saving medications and interventions to unhoused populations.
Presenter(s):
Ed Hayes: Assistant Superintendent at Franklin County Sheriff’s Office, Administrative Director of the FCSO OTP and Rachel Katz, NP Director, Addiction Services, Friends of the Homeless (FOH), Medical Respite, CNP
Credit Available:
CE Credit(s): No
Certificate: Certificate of Attendance, 1-hour
Transitioning from jails and prisons back into the community can be especially difficult for people with opioid use disorders (OUD). Research suggests that opioid use overdose increases dramatically within the first 30 days of citizens returning to the community. Further, individuals recently released from incarceration face a risk of opioid overdose ten times greater than the general public. During these transitions it is critical that people receive seamless and appropriate resources in order to prevent overdose and return to use. This proper transition can help lower health care costs, hospitalizations and emergency department visits, as well as decrease mortality and recidivism for justice-involved individuals, yet at this time only 13 states have sought Medicaid waivers to provide SUD services pre-release. Join us today as we explore how programs can successfully develop services to ensure returning citizens receive appropriate care to address OUD.
Presenter(s):
Bobby Mukkamala, MD and Elizabeth Salisbury-Afshar, MD
Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Credit
Opioid use disorder is a chronic disease that affects many and can be effectively treated. Evidence-based treatment for opioid use disorder (OUD), as well as harm reduction initiatives, can help individuals maintain in treatment and mitigate risks of relapse. In this episode, we’ll discuss medications for opioid use disorder (MOUD) as well as OUD treatment considerations and standards of care. The discussion will also include barriers that can stand in the way of those seeking treatment.
Psychiatric pharmacists are advanced practice clinical pharmacists committed to being part of an interdisciplinary team treating substance use disorders, often in combination with serious mental illness. The following SUD toolkits were developed to further the knowledge of pharmacists and other healthcare professionals.
The purpose of this guide is to provide practical clinical practice-based guidance, based on available research combined with emerging clinical experience, on the use of buprenorphine in the treatment of individuals using fentanyl and other highly potent synthetic opioids. 
Presenter(s):
Maria Manriquez, M.D., FACOG, FASAM, PMH-C; Tara Sundem, APRN, NNP-BC; and Tawni Carson
Credit Available:
CE Credit(s): No
Certificate: Certificate of Attendance, 1-hour
Opioid use disorder (OUD) can be a fatal addiction with complex implications for new and/or expecting mothers. OUD challenges can lead to many complications for mother and child, including low birth weight, clinical challenges with medical dosing and increased risk of accidental death. In the U.S. alone, a baby is born passively dependent every 15 minutes. To ensure best health outcomes for both mother and child, policies must allow engagement in evidence-based treatment and protect clients from legal ramifications. Hear from a physician, clinic director and an individual with lived experience to broaden understandings about the treatment and policy landscape for pregnant and postpartum women with OUD.
Presenter(s):
Jonathan Craig Allen, MD, FASAM, and Marc Fishman, MD
Credit Available:
CE Credit(s): Yes
Designations: Pharmacy CE Credit, AMA PRA Category 1 Credit™, AAPA Category 1 CME, Nursing Contact Hours, Social Work CE Credit, Interprofessional Continuing Education (IPCE) Credit
Research indicates a lack of training and programming specific to treating and managing co-occurring opioid and stimulant use disorders, despite the increased risk of overdose bolstered by the ever-changing and adulterated drug supply. While MOUD is the gold standard of care for treating OUD, there are no FDA-approved medications for treating stimulant use disorder, though behavioral therapies like contingency management have been well-studied. These challenges highlight the need to identify promising treatment strategies to ensure individuals with co-occurring opioid and stimulant use disorders are effectively engaged in care to prevent overdose. This session will equip BH providers and organizations in this space, including Community Behavioral Health Clinics (CCBHCs), with the tools necessary to effectively engage and provide quality, team-based care and services to individuals with co-occurring opioid and stimulant use disorders in order to improve health outcomes, reduce overdose risk, and support long-term recovery.
Presenter(s):
Roberto D. Sanchez, DO and Ali Abbas Asghar-Ali, MD
Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Credit™, AAPA Category 1 CME, Social Work CE Credit, Pharmacy CE Credit, Interprofessional Continuing Education (IPCE) Credit
The number of older adults is projected to exceed 72.1 million people by 2030 and members of the baby boomer generation have the highest rates of early life substance use which increases likelihood of substance use in later life. With rates of SUDs growing in older individuals, this population is experiencing mood and anxiety disorders, sleep disorders, cognitive impairments, sleep disruption, hepatic complications, and greater physical disability as co-morbid symptoms of substance use and aging. This webinar aims to improve awareness of the occurrence and impact of SUD as well as teach geriatric SUD screening tools. Finally, the webinar will offer recommendations for pharmacologic and psychosocial treatments for SUD in older adults.
Presenter(s):
Jeanne Manubay, MD
Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Credit™, AAPA Category 1 CME, Social Work CE Credit, Nursing Contact Hours, Pharmacy CE Credit, Interprofessional Continuing Education (IPCE) Credit
Given the high prevalence of substance use disorders among primary care patients, as well as the continuing epidemic of opioid use disorders, it is important to routinely screen your patients for substance use disorders. This module describes the SBIRT model (Screening, Brief Intervention, Referral to Treatment), an evidence-based practice that has shown significant success in varied clinic settings at reducing alcohol and illicit substance use. Validated, structured screening tools are provided and the components of how to implement brief interventions with your patients are described. The module also discusses approved treatments for substance use disorders, as well as guidelines for when to refer your patient for other options.​
Presenter(s):
Larissa Mooney, MD, Professor of Clinical Psychiatry; Director, Division of Addiction Psychiatry; UCLA Department of Psychiatry and Biobehavioral Sciences
Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Credit™, AAPA Category 1 CME, Nursing Contact Hours, Pharmacy CE Credit, Interprofessional Continuing Education (IPCE) Credit
Alcohol use disorder (AUD) is commonly encountered in clinical settings, and FDA approved medications are available. This module reviews and compares pharmacological treatments for individuals with AUD, including acamprosate, disulfiram, and naltrexone (oral and long-acting intramuscular formulations), as well as non-approved (off-label) options including topiramate and gabapentin. Diagnosis of AUD and definitions of binge drinking and “at risk” drinking levels (per US Dietary Guidelines) are discussed. Effects of alcohol use on the brain, including neurotransmitter effects and withdrawal symptoms, are also reviewed. The module concludes with discussion of a case vignette in which medication options for AUD are considered.
Loading more
Rick Garcia, MD, Roger Chou, MD

Education and Training

Clinical support is provided through online modules, webinars, resources, podcasts and videos.

2018 Steering Committee Meeting

Stay in the loop!

Sign up to stay up to date with current content, news and events.